This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Postoperative Cyclic Oral Contraceptive Use for the Prevention of Endometrioma Recurrence

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified March 2010 by Samsung Medical Center.
Recruitment status was:  Not yet recruiting
Information provided by:
Samsung Medical Center Identifier:
First received: March 23, 2010
Last updated: March 24, 2010
Last verified: March 2010

Ovarian endometriotic cyst (endometrioma) is one of the most common endometriotic lesions, and conservative laparoscopic surgery is the treatment of choice. However, the recurrence after surgery is common.

As repetitive surgery leads to morbidities and ovarian function decrease, recurrence after surgery frustrates both patients and clinicians. In this aspect, medical treatments have been offered after surgery to prevent or delay the recurrence. Gonadotropin-releasing hormone agonist (GnRHa) is frequently used in women with advanced endometriosis, but the efficacy is rather controversial. On the other hand, it has been demonstrated that oral contraceptives (OCs) could reduce or delay endometrioma recurrence, but data are still limited. Consequently, no one type of postoperative medical therapy has been shown to be superior in reducing the recurrence of endometrioma.

The rationale of postoperative medical therapy is that it could eradicate microscopic lesions which were not found and not treated sufficiently during surgery. Therefore, the maintenance of strongly suppressed condition induced by postoperative GnRHa treatment by addition of OCs could be a promising treatment to prevent the recurrence, but it has not been widely investigated.

We performed this retrospective cohort study to evaluate the efficacy of cyclic monophasic low-dose OCs as a maintenance therapy after GnRHa treatment for the suppression of endometrioma recurrence.


Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Efficacy of Postoperative Cyclic Oral Contraceptive Use After Gonadotropin-releasing Hormone Agonist for the Prevention of Endometrioma Recurrence

Resource links provided by NLM:

Further study details as provided by Samsung Medical Center:

Primary Outcome Measures:
  • recurrence rate of endometrioma [ Time Frame: 60 months ]

Estimated Enrollment: 232
Study Start Date: March 2010
Estimated Study Completion Date: March 2010
Estimated Primary Completion Date: March 2010 (Final data collection date for primary outcome measure)
OC use
OC use after postoperative gonadotropin-releasing hormone agonist treatment
OC non-use
Only postoperative gonadotropin-releasing hormone agonist treatment


Ages Eligible for Study:   15 Years to 49 Years   (Child, Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Reproductive aged women who underwent conservative laparoscopic surgery for ovarian endometrioma and followed up at Samsung Medical Center between January 2000 and December 2007.

Inclusion Criteria:

  1. reproductive aged women who underwent conservative laparoscopic ovarian surgery for endometrioma (ASRM stage III/IV) which was confirmed by pathologic inspection
  2. women who were given postoperative GnRHa injections every 28 days for 3 or 6 months
  3. women with no residual lesion confirmed by ultrasonography after surgery
  4. women who were followed up for over 12 months after surgery.

Exclusion Criteria:if they had

  1. undergone hysterectomy during an operation
  2. been given GnRHa injections more than 6 times
  3. been given other types of postoperative treatment (progestin or intrauterine device)
  4. a history of previous pelvic surgery for endometriosis
  5. a history of hormonal treatment before surgery
  6. been diagnosed as menopause after surgery
  7. contraindications to OCs
  8. been identified ovarian endometriomas within 6 months of postoperative evaluation
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01092494

Contact: DooSeok Choi, MD, PhD 82-2-3410-3514

Korea, Republic of
Samsung Medical Center Not yet recruiting
Seoul, Korea, Republic of, 135-710
Contact: DooSeok Choi   
Sponsors and Collaborators
Samsung Medical Center
Study Director: DooSeok Choi Samsung Medical Center
  More Information

Responsible Party: DooSeok Choi, Samsung Medical Center Identifier: NCT01092494     History of Changes
Other Study ID Numbers: 2010-02-020
Study First Received: March 23, 2010
Last Updated: March 24, 2010

Keywords provided by Samsung Medical Center:
Endometrioma recurrence
oral contraceptives
gonadotropin-releasing hormone agonist

Additional relevant MeSH terms:
Disease Attributes
Pathologic Processes
Genital Diseases, Female
Contraceptives, Oral
Contraceptive Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Contraceptive Agents, Female
Reproductive Control Agents processed this record on June 23, 2017